Mevastatin

SKU: orb1310389

Description

Mevastatin (ML236B), the first statin clinically trialed, is a fungal-derived HMG-CoA reductase inhibitor. It serves as a foundational research tool for studying cholesterol biosynthesis and has been utilized in both in vitro enzymatic assays and in vivo models of hyperlipidemia.

Research Area

Cell Biology, Infectious Disease & Virology, Metabolism Research

Key Properties

• CAS Number: 73573-88-3
• MW: 390.51
• Purity: 99.12%
• Formula: C₂₃H₃₄O₅
• SMILES: C(C[C@@H]1C[C@@H](O)CC(=O)O1)[C@@H]2[C@]3([C@@H](OC([C@H](CC)C)=O)CCC=C3C=C[C@@H]2C)[H]
• Target: Autophagy,HMG-CoA Reductase,Antibacterial,Antibiotic,Lipid,Apoptosis
• Solubility: Ethanol:< 1 mg/mL (insoluble or slightly soluble);DMSO:83.33 mg/mL (213.39 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (5.12 mM);H2O:< 1 mg/mL (insoluble or slightly soluble)

Bioactivity

• Target IC50:
  HMG-CoA reductase:1 nM(ki)
• In Vivo:
  The bicyclic portion of Mevastatin binds to the active site of coenzyme A. Mevastatin elevates eNOS mRNA and protein levels, reduces infarct size, and ameliorates neurological deficits in a dose- and time-dependent manner. At a concentration of 0.01 pg/mL (26 nM), Mevastatin can reduce cholesterol synthesis by 50% compared with the control group.
• In Vitro:
  Mevastatin competitively inhibits HMG-CoA reductase, subsequently reducing cholesterol synthesis in the liver. After 14 days of high-dose treatment, a more than 30% increase in baseline absolute cerebral blood flow was observed. Oral administration of Mevastatin at doses of 5 mg/kg and 20 mg/kg led to reductions in serum cholesterol levels 3 hours post-administration, with the 20 mg/kg dosage decreasing serum cholesterol by approximately 30%.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

eNOS, EGFR, Inhibitor, HMG-CoA reductase, HMG-CoA Reductase (HMGCR), HMGCoA Reductase, HMGCR, HMGCoAReductase, NF-κB, neuroprotection, ML236B, Mevastatin, lipid-lowering, inhibit, BMP-2, cardiovascular, Autophagy, Bacterial, Antibiotic, Apoptosis, CES1, Compactin, Statins, phosphorylation, RANKL

Compound Identifiers

PubChem CID

64715